Table 1.
Sample Demographics
| Healthy Subjects |
Psychosis | Statistics | Contrasts | ||||||
|---|---|---|---|---|---|---|---|---|---|
| SCZ | BPP | ||||||||
| N=60 | N=77 | N=40 | F/t/x2 | p | |||||
| Gender (male:female) | 38:22 | 53:24 | 23:17 | 1.52 | .47 | -- | |||
| Race (White:AA:Other) | 39:15:6 | 54:21:2 | 32:6:2 | 5.81 | .21 | -- | |||
| Clinical Status (% first episode) | -- | 44.2 | 40.0 | 0.19 | .67 | -- | |||
| Mood Stabilizer Use (%) | -- | 28.6 | 70.0 | 18.46 | <.001a | -- | |||
| Mean | SD | Mean | SD | Mean | SD | ||||
| Age | 29.27 | 9.45 | 27.43 | 9.71 | 29.20 | 11.19 | 0.72 | .49 | -- |
| Premorbid IQ | 109.90 | 6.73 | 102.01 | 10.08 | 105.53 | 9.93 | 12.66 | <.001 | HS>SCZ |
| SCIP Global Cognition z-score | 0.29 | 0.59 | −0.80 | 0.82 | −0.29 | 0.90 | 33.83 | <.001 | HS>BP>SCZ |
| Median Signal-to-Noise Ratio | 58.87 | 14.15 | 61.31 | 13.85 | 60.49 | 14.33 | 0.51 | .60 | -- |
| Median Voxel Displacement | 0.05 | 0.02 | 0.05 | 0.02 | 0.05 | 0.02 | 0.33 | .72 | -- |
| PANSS Positive | -- | -- | 14.43 | 8.27 | 10.83 | 6.26 | 2.42 | .02 | -- |
| PANSS Negative | -- | -- | 13.62 | 5.41 | 9.80 | 2.73 | 4.20 | <.001 | -- |
| PANSS General | -- | -- | 27.53 | 7.83 | 23.75 | 6.48 | 2.62 | .01 | -- |
| CPZ Equivalents | -- | -- | 354.64 | 199.53 | 231.84 | 160.81 | 2.65 | .01 | -- |
| Illness Duration (Months)b | -- | -- | 75.00 | 95.75 | 72.51 | 88.44 | 0.14 | .89 | -- |
Abbreviations: SCZ=Schizophrenia; BPP=Bipolar with Psychotic Features; HS=Healthy Subjects; SCIP=Screen for Cognitive Impairment in Psychiatry; PANSS=Positive and Negative Syndrome Scale; CPZ=Chlorpromazine
a
The groups did not differ in mood stabilizer dose: t(44)=−0.27, p=.79.
b
Average duration of illness was not significantly associated with any of the significant corticostriatal connectivity estimates (ps> .45).